Literature DB >> 1721347

Correlation of rejection episodes with FK 506 dosage, FK 506 level, and steroids following primary orthotopic liver transplant.

A B Jain1, S Todo, J J Fung, R Venkataramanan, R Day, J Bryant, K M Abu-Elmagd, M Alessiani, S Takaya, A Tzakis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1721347      PMCID： PMC3018886     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  3 in total

1.  Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy.

Authors:  S Takaya; R Duquesnoy; Y Iwaki; J Demetris; A Yagihashi; O Bronsther; S Iwatsuki; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

2.  Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506.

Authors:  A B Jain; J J Fung; S Todo; M Alessiani; S Takaya; K Abu-Elmagd; A Tzakis; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

3.  One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults.

Authors:  S Todo; J J Fung; A Tzakis; A J Demetris; A Jain; M Alessiani; S Takaya; R Day; R Gordon; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066
  3 in total
  10 in total

Review 1.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

2.  Does tacrolimus offer virtual freedom from chronic rejection after primary liver transplantation? Risk and prognostic factors in 1,048 liver transplantations with a mean follow-up of 6 years.

Authors:  A Jain; A J Demetris; R Kashyap; K Blakomer; K Ruppert; A Khan; S Rohal; T E Starzl; J J Fung
Journal:  Liver Transpl       Date:  2001-07       Impact factor: 5.799

3.  What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients.

Authors:  A Jain; J Reyes; R Kashyap; S Rohal; K Abu-Elmagd; T Starzl; J Fung
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

4.  Primary adult liver transplantation under tacrolimus: more than 90 months actual follow-up survival and adverse events.

Authors:  A B Jain; R Kashyap; J Rakela; T E Starzl; J J Fung
Journal:  Liver Transpl Surg       Date:  1999-03

Review 5.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

6.  Tacrolimus-related adverse effects in liver transplant recipients: its association with trough concentrations.

Authors:  Joy Varghese; Mettu Srinivasa Reddy; Kota Venugopal; Rajasekhar Perumalla; Gomathy Narasimhan; Olithselvan Arikichenin; Vivekanandan Shanmugam; Naresh Shanmugam; Vijaya Srinivasan; Venkataraman Jayanthi; Mohamed Rela
Journal:  Indian J Gastroenterol       Date:  2014-04-18

Review 7.  Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

Authors:  D H Peters; A Fitton; G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

Review 8.  Clinical pharmacokinetics of tacrolimus.

Authors:  R Venkataramanan; A Swaminathan; T Prasad; A Jain; S Zuckerman; V Warty; J McMichael; J Lever; G Burckart; T Starzl
Journal:  Clin Pharmacokinet       Date:  1995-12       Impact factor: 6.447

Review 9.  Mechanisms of clinically relevant drug interactions associated with tacrolimus.

Authors:  Uwe Christians; Wolfgang Jacobsen; Leslie Z Benet; Alfonso Lampen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 10.  Microbial drug discovery: 80 years of progress.

Authors:  Arnold L Demain; Sergio Sanchez
Journal:  J Antibiot (Tokyo)       Date:  2009-01-09       Impact factor: 2.649
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.